JP2025165976A5 - - Google Patents

Info

Publication number
JP2025165976A5
JP2025165976A5 JP2025120874A JP2025120874A JP2025165976A5 JP 2025165976 A5 JP2025165976 A5 JP 2025165976A5 JP 2025120874 A JP2025120874 A JP 2025120874A JP 2025120874 A JP2025120874 A JP 2025120874A JP 2025165976 A5 JP2025165976 A5 JP 2025165976A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
oligonucleotide according
chiral
independently
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025120874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025165976A (ja
Filing date
Publication date
Priority claimed from JP2022520901A external-priority patent/JP7766589B2/ja
Application filed filed Critical
Publication of JP2025165976A publication Critical patent/JP2025165976A/ja
Publication of JP2025165976A5 publication Critical patent/JP2025165976A5/ja
Pending legal-status Critical Current

Links

JP2025120874A 2019-10-06 2025-07-17 オリゴヌクレオチド組成物及びその使用方法 Pending JP2025165976A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962911334P 2019-10-06 2019-10-06
US62/911,334 2019-10-06
US202062959917P 2020-01-11 2020-01-11
US62/959,917 2020-01-11
US202063022559P 2020-05-10 2020-05-10
US63/022,559 2020-05-10
US202063069696P 2020-08-24 2020-08-24
US63/069,696 2020-08-24
JP2022520901A JP7766589B2 (ja) 2019-10-06 2020-10-06 オリゴヌクレオチド組成物及びその使用方法
PCT/US2020/054436 WO2021071858A1 (en) 2019-10-06 2020-10-06 Oligonucleotide compositions and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022520901A Division JP7766589B2 (ja) 2019-10-06 2020-10-06 オリゴヌクレオチド組成物及びその使用方法

Publications (2)

Publication Number Publication Date
JP2025165976A JP2025165976A (ja) 2025-11-05
JP2025165976A5 true JP2025165976A5 (https=) 2026-03-19

Family

ID=75437497

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520901A Active JP7766589B2 (ja) 2019-10-06 2020-10-06 オリゴヌクレオチド組成物及びその使用方法
JP2025120874A Pending JP2025165976A (ja) 2019-10-06 2025-07-17 オリゴヌクレオチド組成物及びその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022520901A Active JP7766589B2 (ja) 2019-10-06 2020-10-06 オリゴヌクレオチド組成物及びその使用方法

Country Status (11)

Country Link
US (1) US20230220384A1 (https=)
EP (1) EP4022059A4 (https=)
JP (2) JP7766589B2 (https=)
KR (1) KR20220076508A (https=)
CN (1) CN114585737A (https=)
AU (1) AU2020363391A1 (https=)
BR (1) BR112022006205A2 (https=)
CA (1) CA3154768A1 (https=)
IL (1) IL291933A (https=)
MX (1) MX2022004101A (https=)
WO (1) WO2021071858A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
BR112016016400A2 (pt) 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
IL320434A (en) 2015-07-22 2025-06-01 Wave Life Sciences Ltd Oligonucleotide preparations and methods
CN108779132B (zh) 2016-03-13 2022-04-15 波涛生命科学有限公司 用于亚磷酰胺和寡核苷酸合成的组合物和方法
JP2019520339A (ja) 2016-06-03 2019-07-18 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． オリゴヌクレオチド、その組成物および方法
WO2017220751A1 (en) 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Single-stranded rna-editing oligonucleotides
CN110352244B (zh) 2016-09-01 2023-03-21 ProQR治疗上市公司Ⅱ 化学修饰的编辑rna的单链寡核苷酸
US11873316B2 (en) 2016-11-23 2024-01-16 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
CA3065523A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
JP2020522510A (ja) 2017-06-02 2020-07-30 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． オリゴヌクレオチド組成物及びその使用方法
US11718638B2 (en) 2017-06-21 2023-08-08 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
EP3664816A4 (en) 2017-08-08 2021-05-19 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES
CA3072110A1 (en) 2017-09-18 2019-03-21 Wave Life Sciences Ltd. Technologies for oligonucleotide preparation
EP3694530A4 (en) 2017-10-12 2021-06-30 Wave Life Sciences Ltd. COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
SG11202009877XA (en) 2018-04-12 2020-11-27 Wave Life Sciences Ltd Oligonucleotide compositions and methods of use thereof
US12391942B2 (en) 2018-05-11 2025-08-19 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
JP2022525541A (ja) * 2019-03-20 2022-05-17 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド調製に有用な技術
WO2022046667A1 (en) * 2020-08-24 2022-03-03 Wave Life Sciences Ltd. Cells and non-human animals engineered to express adar1 and uses thereof
KR20230118716A (ko) * 2020-11-08 2023-08-11 웨이브 라이프 사이언시스 리미티드 올리고뉴클레오티드 조성물 및 이의 방법
EP4363574A1 (en) * 2021-06-29 2024-05-08 Korro Bio, Inc. Methods and compositions for adar-mediated editing
US20230194709A9 (en) * 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
EP4396354A4 (en) * 2021-09-26 2025-12-03 Wave Life Sciences Ltd OLIGONUCLEOTIDE COMPOSITIONS AND ASSOCIATED PROCESSES
EP4479535A1 (en) 2022-02-14 2024-12-25 ProQR Therapeutics II B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2023220428A1 (en) * 2022-05-12 2023-11-16 Wave Life Sciences Ltd. Compositions for editing ass1 transcripts and methods thereof
US20250302995A1 (en) * 2022-05-12 2025-10-02 Chikdu Shakti Shivalila Oligonucleotide compositions and methods thereof
US20260027237A1 (en) 2022-07-15 2026-01-29 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
JP2025524566A (ja) 2022-07-15 2025-07-30 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ Ａｄａｒ媒介ｒｎａ編集のためのオリゴヌクレオチドおよびその使用
JP2025525564A (ja) * 2022-07-18 2025-08-05 エフ． ホフマン－ラ ロシュ アーゲー オリゴヌクレオチドの編集
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024110565A1 (en) 2022-11-24 2024-05-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
WO2024114908A1 (en) 2022-11-30 2024-06-06 Eberhard Karls Universität Tübingen Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
AU2023390632A1 (en) 2022-12-09 2025-07-10 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
EP4669750A2 (en) 2023-02-21 2025-12-31 Vib Vzw SYNAPTOGYRIN-3 EXPRESSION INHIBITORS
WO2024175588A1 (en) 2023-02-21 2024-08-29 Vib Vzw Oligonucleotides for modulating synaptogyrin-3 expression
EP4432289A1 (en) 2023-03-15 2024-09-18 Shape Therapeutics Inc. Generative sequence screening with conditional gans, diffusion models, and denoising diffusion conditional gans
EP4689110A1 (en) 2023-03-24 2026-02-11 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of neurological disorders
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
EP4688143A1 (en) 2023-03-27 2026-02-11 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of liver disease
TW202516003A (zh) 2023-06-16 2025-04-16 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ 用於治療神經退化性疾病之反義寡核苷酸
WO2025015335A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
CN121794378A (zh) 2023-08-15 2026-04-03 艾尔纳公司 用于rna编辑的化学修饰的反义寡核苷酸（aso）及组合物
WO2025051946A1 (en) 2023-09-07 2025-03-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
AU2024354150A1 (en) * 2023-09-28 2026-03-12 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2025073902A1 (en) 2023-10-06 2025-04-10 Eberhard Karls Universität Tübingen Chemical and sequence optimisation of antisense oligonucleotides for adar-mediated rna editing
WO2025083268A1 (en) 2023-10-20 2025-04-24 Airna Corporation Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing
WO2025096809A1 (en) 2023-10-31 2025-05-08 Korro Bio, Inc. Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
WO2025172372A1 (en) * 2024-02-12 2025-08-21 Airna Corporation Conjugate for targeted delivery of an antisense oligonucleotide
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2026050243A1 (en) 2024-08-26 2026-03-05 Korro Bio, Inc. Galnac conjugated oligonucleotides for rna editing
WO2026060374A2 (en) 2024-09-16 2026-03-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en) 2024-09-30 2026-04-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014169206A2 (en) * 2013-04-11 2014-10-16 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
BR112016016400A2 (pt) * 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
RU2708237C2 (ru) * 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
US10787664B2 (en) * 2015-05-26 2020-09-29 City Of Hope Compounds of chemically modified oligonucleotides and methods of use thereof
IL295755A (en) * 2015-10-09 2022-10-01 Wave Life Sciences Ltd Oligonucleotide compositions and methods thereof
JP2019520339A (ja) * 2016-06-03 2019-07-18 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． オリゴヌクレオチド、その組成物および方法
CN110352244B (zh) * 2016-09-01 2023-03-21 ProQR治疗上市公司Ⅱ 化学修饰的编辑rna的单链寡核苷酸
US11718638B2 (en) * 2017-06-21 2023-08-08 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis

Similar Documents

Publication Publication Date Title
JP2025165976A5 (https=)
JP7740719B2 (ja) ホスホルアミダイト化学を使用する骨格修飾モルホリノオリゴヌクレオチド及びキメラの合成
JP2023548584A5 (https=)
KR100875003B1 (ko) 누클레오시드의 위치 변형에 의한 올리고누클레오티드 ＣｐＧ 매개성 면역 자극의 조절
TWI541024B (zh) 反義核酸
JP3831407B2 (ja) メチルホスホン酸エステル、その製造方法およびその使用
US7176296B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
JP5520818B2 (ja) Ｒｎａ合成のためのチオ炭素保護基
JP6613143B2 (ja) ２’ヌクレオシド間結合を含有する低分子干渉核酸（ｓｉＮＡ）分子
US6140482A (en) Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same
JP2022519019A5 (https=)
US7105495B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
JP2003520811A (ja) ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節
EP3728591B1 (en) Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
WO2019182037A1 (ja) 毒性が低減されたアンチセンスオリゴヌクレオチド
JPWO2019022196A1 (ja) 一本鎖オリゴヌクレオチド
JP2024544067A5 (https=)
JP7624221B2 (ja) 一本鎖ポリヌクレオチド
EP0749436A1 (en) Compositions and methods for use in the synthesis of oligonucleotides
DE69725440T2 (de) 2-substituierte nukleosid- und oligonukleotid- derivate
JP4791665B2 (ja) 接合体ならびにそれらの製造方法および生体膜を横切り分子を輸送するためのそれらの使用
WO1994004550A1 (en) Cholesteryl-modified triple-helix forming oligonucleotides and uses thereof
JP2000509724A (ja) ヌクレオチド又はオリゴヌクレオチドホスホロアミダイトの合成方法
JPWO2021187392A5 (https=)
JP2025518487A5 (https=)